# An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype

## Metadata
**Authors:** S Panserat, C Mura, N GÃ©rard, M Vincent-Viry, M M Galteau, E Jacoz-Aigrain, R Krishnamoorthy
**Journal:** British Journal of Clinical Pharmacology
**Date:** 1995 Oct
**DOI:** [10.1111/j.1365-2125.1995.tb04558.x](https://doi.org/10.1111/j.1365-2125.1995.tb04558.x)
**PMID:** 8554938
**PMCID:** PMC1365155
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365155/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC1365155/pdf/brjclinpharm00003-0072.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC1365155/pdf/brjclinpharm00003-0072.pdf)

*Note: This is a scanned document with limited structured text. Full content available in PDF.*

## Abstract

1. The study of the CYP2D genotype and phenotype of a Caucasian family revealed that a XbaI-9 kb allele was associated with the poor metabolizer phenotype. 2. A Polymerase Chain Reaction (PCR)-based assay showed that the previously described mutations D6A and D6B are not associated with the XbaI-9 kb allele. 3. To explore the molecular basis of the poor metabolizer phenotype associated with the XbaI-9 kb allele, complete sequencing of the nine exons and intron-exon boundaries of the CYP2D6 gene was undertaken after amplification by PCR. 4. All the exons were successfully amplified using CYP2D6 gene-specific primers except exon 1 which required a combination of CYP2D7 gene-specific 5' primer and a CYP2D6 gene-specific 3' primer. 5. Sequence data derived from this amplified product revealed that the XbaI-9 kb allele corresponds to a novel rearrangement of the locus. This involved a deletion of an approximately 20 kilobase (kb) DNA segment generating a hybrid 5' CYP2D7/CYP2D6 3' gene. 6. The chimeric gene is non-functional presumably due to an insertion in exon 1 (characteristic of the exon 1 of the CYP2D7 gene) which causes a shift in the reading frame with premature termination of translation.

## Full Text (Scanned Pages)

### Page 1
![361](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/0b4f4f6686e9/brjclinpharm00003-0072.png)

### Page 2
![362](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/39bbb97d9328/brjclinpharm00003-0073.png)

### Page 3
![363](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/e9eb6e012e09/brjclinpharm00003-0074.png)

### Page 4
![364](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/a00eeb9a0497/brjclinpharm00003-0075.png)

### Page 5
![365](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/692b89b47df9/brjclinpharm00003-0076.png)

### Page 6
![366](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/9c8224322567/brjclinpharm00003-0077.png)

### Page 7
![367](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00ea/1365155/04a23b403145/brjclinpharm00003-0078.png)
